On December 4, 2025 Syntara Limited (ASX: SNT), a clinical-stage drug development company, reported that two posters detailing the preclinical findings and clinical data1 from its Phase 2a trial evaluating amsulostat (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF) will be presented at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (ASH) (Free ASH Whitepaper), taking place in Orlando, Florida, from 6-9 December 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
One poster presentation, titled "A Phase 1/2a Trial of Amsulostat, a Novel Pan-Lysyl Oxidase Inhibitor, in Patients with Advanced Myelofibrosis as an Add-On to Ruxolitinib Treatment for Up to 52 Weeks," will be featured in the session "Myeloproliferative Syndromes: Clinical and Epidemiological" on Saturday 6 December (EST).
In a concurrent "Bone Marrow Microenvironment" session, Syntara will also present preclinical research highlighting amsulostat-sensitive, lysyl oxidase–mediated modulation of growth factor signaling, titled "Lysyl Oxidases Directly Control Cell Surface Abundance of Platelet-Derived Growth Factor Receptors and Signaling in Osteoblasts."
Attending the ASH (Free ASH Whitepaper) Annual Meeting on behalf of Syntara will be Dr. Jana Baskar, CMO, Dr. Wolfgang Jarolimek, Head of Drug Discovery, and Gary Phillips, CEO.
Mr Phillips said: "The ASH (Free ASH Whitepaper) Annual Meeting and Exposition is the leading global forum for advancing research in haematological malignancies. We welcome the opportunity to present our recent clinical and mechanism of action data on amsulostat to the global haematology community and to discuss future clinical and commercial pathways with potential collaborators."
Syntara has received feedback from the US Food and Drug Administration (FDA) on the recommended pathway for further development of amsulostat and, with the support of an experienced and well renowned advisory board, is progressing the protocol for the next trial. Amsulostat is also being evaluated in two Phase 1c/2 trials of myelodysplastic syndrome which are currently recruiting and expected to deliver preliminary results in 2026.
(Press release, Syntara, DEC 4, 2025, https://mcusercontent.com/add2e2fa70ec3d0eeaf2a93cc/files/a7cc5fc7-eb21-174a-d2db-66f2331f2272/03033592.pdf [SID1234661128])